Stock Market & Financial Investment News

News Breaks January 17, 2013 07:15 EDT SHPG, AZN AstraZeneca rumored to be interested in Shire, Guardian reports The Guardian reports speculation that AstraZeneca (AZN) will bid for Shire (SHPG). Reference Link News For SHPG;AZN From The Last 14 Days Check below for free stories on SHPG;AZN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 09:29 EDT AZN AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). May 20, 2013 10:03 EDT SHPG Shire advances after report renews takeover speculation Subscribe for More Information 07:27 EDT SHPG American Psychiatric Association to host annual meeting Subscribe for More Information 07:01 EDT SHPG Sangamo BioSciences announces positive data for Vivo Protein platform Sangamo BioSciences (SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire (SHPG) to develop ZFP Therapeutics for both hemophilia A and B using this approach. 06:30 EDT SHPG Leerink estimates Shire takeout value at least $110 per share Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. 06:25 EDT SHPG Shire may return cash to thwart takeover, Daily Mail reports Subscribe for More Information May 17, 2013 10:36 EDT AZN Leerink's major/specialty pharma analyst holds analyst/Industry conference call Subscribe for More Information 08:41 EDT AZN Impax commenced shipment of authorized generic Zomig Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. May 14, 2013 07:24 EDT AZN, SHPG EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 16:53 EDT AZN Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link 15:55 EDT AZN Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says Subscribe for More Information May 10, 2013 11:48 EDT AZN Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 10:00 EDT SHPG On The Fly: Analyst Downgrade Summary Subscribe for More Information 05:42 EDT SHPG Shire downgraded to Neutral from Overweight at JPMorgan May 9, 2013 12:24 EDT SHPG Shire unit wins patent trial against Watson regarding LIALDA Shire (SHPG), announces that its subsidiary, Shire Development, has prevailed in its litigation against Watson Pharmaceuticals, Watson Laboratories-Florida, Watson Pharma. and Watson Laboratories in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent. 10:17 EDT SHPG, AZN Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.